For antiallergics, contraceptives, DMDs, insulin, Parkinson’s disease drugs, psoriasis drugs and sedatives, there were no significant differences for the stratification of patients by polypharmacy (FDR>0.05). The gene discussed is INS; the disease is Parkinson disease.